Description: BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Home Page: www.biolinerx.com
Modi’in Technology Park
Hevel Modi'in,
7177871
Israel
Phone:
972 8 642 9100
Officers
| Name | Title |
|---|---|
| Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA | Chief Executive Officer |
| Ms. Mali Zeevi CPA, CPA | Chief Financial Officer |
| Dr. Ella Sorani Ph.D. | Chief Development Officer |
| Ms. Holly W. May M.B.A. | President of BioLineRx USA |
| Mr. John Lacey | Head of Corporate Communications & Investor Relations |
| Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. | Head of BD & Strategic Advisor |
| Mr. Raziel Fried | Treasurer & Budgetary Control Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.675 |
| Price-to-Sales TTM: | 1.4966 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 79 |